Incorporating real-world patient and clinician preferences in simulating Integrated Models of Prenatal care for Addiction and Hepatitis C Treatment (IMPACT) - PROJECT SUMMARY The intertwined opioid use disorder (OUD) and hepatitis C virus (HCV) infection epidemics pose a substantial public health burden in the U.S., and affect 9.4 and 4 million Americans, respectively. Injection drug use is the main risk factor for HCV, and women who inject drugs face a 35% higher HCV risk than men. However, only half of Americans with OUD and one-third with HCV have received treatment, with lower rates among women, especially during pregnancy. During pregnancy, women longitudinally engage with healthcare through prenatal care, with 98% accessing services—creating a strategic intervention window. The American College of Obstetricians and Gynecologists recommends medications for OUD during pregnancy, and infectious disease society guidelines encourage HCV treatment in pregnancy after discussing the benefits and risks given growing safety and efficacy data. However, few obstetricians treat OUD or HCV. Treating OUD and HCV during pregnancy could improve maternal and infant health, but to design successful treatment programs, we must understand preferences of pregnant women with OUD and HCV about how they would like to be treated, including their willingness to accept treatment. We also must learn how we can support and empower prenatal clinicians to make it feasible for them to treat OUD and HCV or work with specialists in their clinics to treat women at this critical time. Additionally, for health systems and policy makers to invest in and recommend programs to treat OUD and HCV in prenatal care, they must provide clinical benefits and be cost-effective. Through the proposed work, we will identify OUD and HCV prenatal care program designs that align with patient and provider preferences and evaluate their health and economic impact through three complementary aims: (1) quantify what program design elements (e.g., who prescribes, how many extra visits, when to start treatment) influence patient willingness to adopt and provider willingness to offer integrated OUD/HCV treatment; (2) build and validate a simulation model incorporating this preference data to project long-term population-level health impacts, including overdoses and infant and adult HCV transmission, of increasing OUD and HCV treatment during pregnancy; and (3) evaluate the cost-effectiveness of patient and clinician-preferred prenatal treatment programs. Our multidisciplinary team combines expertise in HCV, addiction medicine, prenatal care, decision modeling, and health economics, and leverages our existing clinical programs and data to determine how to scale up OUD and HCV treatment in prenatal care to improve maternal, infant, and population-level health. By treating both conditions during the critical window of pregnancy, this approach has the potential to improve maternal health outcomes, prevent HCV transmission to infants, and reduce community-level HCV incidence. This will provide a scalable model to address the intersecting OUD and HCV epidemics, transform prenatal care delivery, and guide US Department of Health and Human Services Healthy People 2030 goals for reducing opioid overdoses and HCV infections.